Published in Genes Cancer on July 01, 2010
CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage. Nucleic Acids Res (2012) 1.16
Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung. Clin Cancer Res (2013) 1.08
Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2012) 1.05
Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy. Mol Oncol (2012) 1.05
Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One (2012) 1.02
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun (2014) 0.96
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci (2015) 0.95
Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol Biol (2012) 0.94
It takes two to tango: Ubiquitin and SUMO in the DNA damage response. Front Genet (2013) 0.90
SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function. Cancer Res (2013) 0.90
Post-translational modifications of the progesterone receptors. J Steroid Biochem Mol Biol (2013) 0.88
Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci (2015) 0.88
Covalent small ubiquitin-like modifier (SUMO) modification of Maf1 protein controls RNA polymerase III-dependent transcription repression. J Biol Chem (2013) 0.87
SUMO-specific proteases/isopeptidases: SENPs and beyond. Genome Biol (2014) 0.85
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer (2015) 0.84
Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing. Nat Immunol (2015) 0.83
Emerging roles of sumoylation in the regulation of actin, microtubules, intermediate filaments, and septins. Cytoskeleton (Hoboken) (2015) 0.83
Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood (2014) 0.82
Detection of differentially expressed genes and association with clinicopathological features in laryngeal squamous cell carcinoma. Oncol Lett (2012) 0.82
SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function. J Biol Chem (2011) 0.80
Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer. J Hematol Oncol (2015) 0.80
SUMOylation of HP1α supports association with ncRNA to define responsiveness of breast cancer cells to chemotherapy. Oncotarget (2016) 0.80
Estrogen receptor alpha and nuclear factor Y coordinately regulate the transcription of the SUMO-conjugating UBC9 gene in MCF-7 breast cancer cells. PLoS One (2013) 0.79
Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells. Exp Ther Med (2014) 0.78
Inhibition of SENP1 induces radiosensitization in lung cancer cells. Exp Ther Med (2013) 0.78
High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer. Am J Cancer Res (2014) 0.78
Expression and cell distribution of SENP3 in the cerebral cortex after experimental subarachnoid hemorrhage in rats: a pilot study. Cell Mol Neurobiol (2014) 0.77
Mapping the SUMOylated landscape. FEBS J (2015) 0.77
Pli1(PIAS1) SUMO ligase protected by the nuclear pore-associated SUMO protease Ulp1SENP1/2. J Biol Chem (2015) 0.77
Inhibition of p53 deSUMOylation exacerbates puromycin aminonucleoside-induced apoptosis in podocytes. Int J Mol Sci (2014) 0.75
Novel SUMO-Protease SENP7S Regulates β-catenin Signaling and Mammary Epithelial Cell Transformation. Sci Rep (2017) 0.75
SUMO and the robustness of cancer. Nat Rev Cancer (2017) 0.75
Retracted High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer. Am J Cancer Res (2015) 0.75
SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation. Int J Mol Sci (2017) 0.75
SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget (2016) 0.75
Screening and identification of SUMP-proteins in sub-acute treatment with diazinon. Iran J Basic Med Sci (2015) 0.75
Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia. Oncol Lett (2016) 0.75
Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1α and with transcription factors Sp1 and Sp3. Oncotarget (2016) 0.75
Inhibition of NEDD8 and FAT10 ligase activities through the degrading enzyme NEDD8 ultimate buster 1: A potential anticancer approach. Oncol Lett (2016) 0.75
SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases. Proteomics (2014) 0.75
Transcriptional Profile and Structural Conservation of SUMO-Specific Proteases in Schistosoma mansoni. J Parasitol Res (2012) 0.75
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer. Biomolecules (2012) 0.75
Genetic Polymorphism of SUMO-Specific Cysteine Proteases - SENP1 and SENP2 in Breast Cancer. Pathol Oncol Res (2016) 0.75
The E3 ligase APC/C-Cdh1 regulates MEF2A-dependent transcription by targeting SUMO-specific protease 2 for ubiquitination and degradation. Cell Cycle (2014) 0.75
Expression and Cell Distribution of SENP3 in Brain Tissue After Traumatic Brain Injury in Mice: A Pilot Study. Cell Mol Neurobiol (2015) 0.75
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
Ubiquitin-like proteins: new wines in new bottles. Gene (2000) 3.46
Identification of three major sentrinization sites in PML. J Biol Chem (1998) 2.54
SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell (2010) 2.52
SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol (2008) 2.35
Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate (2005) 2.19
A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem (2004) 2.13
Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. J Biol Chem (1997) 1.86
The SUMO-specific protease SENP5 is required for cell division. Mol Cell Biol (2006) 1.81
A role for Ubc9 in tumorigenesis. Oncogene (2005) 1.76
A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun (2005) 1.68
The fast-growing business of SUMO chains. Mol Cell (2008) 1.66
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J (2009) 1.41
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem (2007) 1.41
Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry (2010) 1.38
Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab (2004) 1.35
Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett (1999) 1.33
Differential PIAS3 expression in human malignancy. Oncol Rep (2004) 1.30
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene (2007) 1.29
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood (2009) 1.18
SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem (2010) 1.16
Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle (2008) 1.13
A fluorescence-resonance-energy-transfer-based protease activity assay and its use to monitor paralog-specific small ubiquitin-like modifier processing. Anal Biochem (2007) 1.10
Proteomic characterization of mouse cytosolic and membrane prostate fractions: high levels of free SUMO peptides are androgen-regulated. J Proteome Res (2008) 0.81
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell (2010) 2.52
Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation (2003) 2.28
Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem (2006) 2.15
Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun (2005) 1.68
Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol (2005) 1.67
Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat Cell Biol (2006) 1.62
Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation (2004) 1.55
Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol Cell (2010) 1.50
Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation (2004) 1.46
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J (2009) 1.41
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem (2007) 1.41
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep (2008) 1.27
Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J Virol (2005) 1.26
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res (2010) 1.26
Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med (2008) 1.24
Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci (2003) 1.20
SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem (2010) 1.16
Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J Biol Chem (2003) 1.15
Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells. J Clin Invest (2015) 1.12
SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 1.11
Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. EMBO J (2010) 1.11
NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell (2011) 1.09
Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by alpha 4 beta 1 integrin/vascular cell adhesion molecule-1 interaction. Circ Res (2007) 1.09
Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol (2008) 1.08
Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J Biol Chem (2010) 1.06
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2012) 1.05
SUMOylation and de-SUMOylation in response to DNA damage. FEBS Lett (2011) 1.03
C-reactive protein: structure affects function. Circulation (2004) 1.00
The pleiotropic effects of statins. Curr Opin Cardiol (2005) 0.99
De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res (2013) 0.99
C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol (2003) 0.95
The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol (2008) 0.89
A new perspective on the biology of C-reactive protein. Circ Res (2005) 0.87
Molecular imaging of mesenchymal stem cell: mechanistic insight into cardiac repair after experimental myocardial infarction. Circ Cardiovasc Imaging (2011) 0.86
Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects. J Vasc Res (2005) 0.84
Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther (2011) 0.84
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Tex Heart Inst J (2009) 0.84
Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest (2015) 0.83
SUMO-specific protease 1 regulates mitochondrial biogenesis through PGC-1α. J Biol Chem (2012) 0.83
Role of C-reactive protein in acute myocardial infarction and stroke: possible therapeutic approaches. Curr Pharm Biotechnol (2012) 0.82
The in vivo functions of desumoylating enzymes. Subcell Biochem (2010) 0.81
NUB1-mediated targeting of the ubiquitin precursor UbC1 for its C-terminal hydrolysis. Eur J Biochem (2004) 0.81
Weighing in on heart failure: the role of SERCA2a SUMOylation. Circ Res (2012) 0.81
An essential role of small ubiquitin-like modifier (SUMO)-specific Protease 2 in myostatin expression and myogenesis. J Biol Chem (2013) 0.80
Ubiquitin, proteasome, and restenosis: a brave new world for cardiovascular research. Circulation (2002) 0.79
Wrestling with heart failure: SUMO-1 to the rescue. Circ Res (2014) 0.79
Fusion of the SUMO/Sentrin-specific protease 1 gene SENP1 and the embryonic polarity-related mesoderm development gene MESDC2 in a patient with an infantile teratoma and a constitutional t(12;15)(q13;q25). Hum Mol Genet (2005) 0.78
A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol (2005) 0.76
Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases. Curr Atheroscler Rep (2004) 0.76
Balancing act during development: lessons from a SUMO-less SF-1. Dev Cell (2011) 0.75
Blood-derived progenitor cells after recanalization of chronic coronary artery occlusions in humans. Circ Res (2005) 0.75
Heparin and bone marrow-derived cell therapy: friend or foe? Circ Res (2012) 0.75
Cardiovascular risk associated with androgen deprivation therapy. Oncology (Williston Park) (2010) 0.75
Microphthalmia-associated transcription factor, melanoma, and renal carcinoma: the small ubiquitin-like modifier connection. Pigment Cell Melanoma Res (2011) 0.75
Cytokine profile and ST-elevation myocardial infarction. Circ Res (2012) 0.75